COVID-19 백신의 포괄적 이해와 현장 적용

키워드

참고문헌 (18)

1. Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
2. Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
3. Voysey M, "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19(AZD1222)vaccine : a pooled analysis of four randomised trials", Lancet, 397, pp.881~891 (2021)
4. Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine", N Engl J Med, 384, pp.403~416 (2021)
5. Shinde V, "Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant", N Engl J Med, 384, pp.1899~1909 (2021)
6. Haas EJ, "Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel : an observational study using national surveillance data", Lancet, 397, pp.1819~1829 (2021)
7. Thompson MG, "Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. locations, December 2020-March 2021", MMWR Morb Mortal Wkly Rep, 70, pp.495~500 (2021)
8. Hall VJ, "COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection(SIREN) : a prospective, multicentre, cohort study", Lancet, 397, pp.1725~1735 (2021)
9. Vasileiou E, "Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland : a national prospective cohort study", Lancet, 397, pp.1646~1657 (2021)
10. "2021년 1분기 코로나19 백신 접종대상자에서 예방접종 초기 분석 결과" (2021)[URL]
11. Choi Won Suk, "COVID-19 Vaccination for People with Comorbidities", Infection and Chemotherapy, 53(1), pp.155~158 (2021), 대한감염학회[DOI]
12. Wallace M, "The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19vaccine in adolescents Aged 12-15 years-United States, May 2021", MMWR Morb Mortal Wkly Rep, 70, pp.749~752 (2021)
13. Tom T. Shimabukuro, "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons", New England Journal of Medicine, 384(24), pp.2273~2282 (2021), Massachusetts Medical Society[DOI]
14. Liu Y, "Neutralizing activity of BNT162b2-elicited serum", N Engl J Med, 384, pp.1466~1468 (2021)
15. Wu K, "Serum neutralizing activity elicited by mRNA-1273 vaccine", N Engl J Med, 384, pp.1468~1470 (2021)
16. Madhi SA, "Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351variant", N Engl J Med, 384, pp.1885~1898 (2021)
17. Emary KRW, "Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2variant of concern 202012", 01 (B.1.1.7): an exploratory analysis of a randomised controlled trial, 2021, pp.397, 1351~1362
18. Laith J. Abu-Raddad, "Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants", New England Journal of Medicine, 385(2), pp.187~189 (2021), Massachusetts Medical Society[DOI]

관련 논문AI추천